SSR411298 is a reversible, orally active compound that selectively inhibits fatty acid amide hydrolase (FAAH). Its potential lies in the field of post-traumaticstressdisorder (PTSD) research.
BRD3731 is a selective inhibitor of GSK3β, demonstrating an IC50 value of 15 nM for GSK3β and 215 nM for GSK3α. Due to its inhibitory properties, BRD3731 holds promise for investigating various medical conditions, including post-traumaticstressdisorder (PTSD), psychiatric disorders, diabetes, and neurodegenerative disorders [1].
Fluvoxamine acid is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive-compulsive disorder (OCD), and is also used to treat major depressive disorder (MDD), and anxiety disorders such as panic disorder and post-traumaticstressdisorder (PTSD).